{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:14:34Z","timestamp":1778055274042,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.acvd.2014.01.009","type":"journal-article","created":{"date-parts":[[2014,3,13]],"date-time":"2014-03-13T01:45:59Z","timestamp":1394675159000},"page":"178-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["New antiplatelet agents in the treatment of acute coronary syndromes"],"prefix":"10.1016","volume":"107","author":[{"given":"Pierre","family":"Sabouret","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Taiel-Sartral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2014.01.009_bib0005","first-page":"e148","volume":"116","author":"Anderson","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2014.01.009_bib0010","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.jacc.2010.09.077","article-title":"Composition of coronary thrombus in acute myocardial infarction","volume":"57","author":"Silvain","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2014.01.009_bib0015","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2007.02.013","volume":"50","author":"Anderson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2014.01.009_bib0020","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2014.01.009_bib0025","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","article-title":"Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial","volume":"110","author":"Fox","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2014.01.009_bib0030","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2014.01.009_bib0035","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O\u2019Gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2014.01.009_bib0040","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2014.01.009_bib0045","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIR.0b013e31820f2f3e","volume":"123","author":"Wright","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2014.01.009_bib0050","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-2003-40669","article-title":"P2Y12, a new platelet ADP receptor, target of clopidogrel","volume":"3","author":"Herbert","year":"2003","journal-title":"Semin Vasc Med"},{"key":"10.1016\/j.acvd.2014.01.009_bib0055","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","article-title":"Identification and biological activity of the active metabolite of clopidogrel","volume":"84","author":"Savi","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.acvd.2014.01.009_bib0060","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2007.12.044","article-title":"Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study","volume":"51","author":"Bonello","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2014.01.009_bib0065","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jcin.2008.01.005","article-title":"Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention","volume":"1","author":"Kereiakes","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.acvd.2014.01.009_bib0070","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","article-title":"Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis","volume":"53","author":"Sibbing","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2014.01.009_bib0075","first-page":"841","article-title":"Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis","volume":"103","author":"Sofi","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.acvd.2014.01.009_bib0080","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2014.01.009_bib0085","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2014.01.009_bib0090","doi-asserted-by":"crossref","first-page":"66e9","DOI":"10.1016\/j.ahj.2006.10.010","article-title":"A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation","volume":"153","author":"Brandt","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2014.01.009_bib0095","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2147\/VHRM.S5699","article-title":"Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"5","author":"Norgard","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.acvd.2014.01.009_bib0100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2014.01.009_bib0105","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2014.01.009_bib0110","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1111\/j.1538-7836.2010.03972.x","article-title":"Randomized, double-blind comparison of effects of abiciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting","volume":"8","author":"Valgimigli","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2014.01.009_bib0115","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction","volume":"5","author":"Alexopoulos","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.acvd.2014.01.009_bib0120","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1160\/TH09-07-0482","article-title":"Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study","volume":"103","author":"Montalescot","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.acvd.2014.01.009_bib0125","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/eurheartj\/ehq494","article-title":"A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial","volume":"32","author":"Angiolillo","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2014.01.009_bib0130","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"Wiviott","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2014.01.009_bib0135","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1161\/CIRCULATIONAHA.104.502815","article-title":"Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial","volume":"111","author":"Wiviott","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2014.01.009_bib0140","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2014.01.009_bib0145","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.thromres.2009.06.029","article-title":"Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis\/hemostasis","volume":"124","author":"van Giezen","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.acvd.2014.01.009_bib0150","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/eurheartj\/ehp296","article-title":"P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use","volume":"30","author":"Wallentin","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2014.01.009_bib0155","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcin.2010.12.011","article-title":"Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping","volume":"4","author":"Alexopoulos","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.acvd.2014.01.009_bib0160","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","article-title":"Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2014.01.009_bib0165","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/CIRCULATIONAHA.109.919456","article-title":"Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2014.01.009_bib0170","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2014.01.009_bib0175","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2014.01.009_bib0180","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"122","author":"James","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2014.01.009_bib0185","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2014.01.009_bib0190","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0022-3565(24)38930-X","article-title":"Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model","volume":"295","author":"Huang","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.acvd.2014.01.009_bib0195","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.jacc.2007.07.058","article-title":"Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes","volume":"50","author":"Storey","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2014.01.009_bib0200","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2014.01.009_bib0205","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.jacc.2007.09.011","article-title":"Universal definition of myocardial infarction","volume":"50","author":"Thygesen","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2014.01.009_bib0210","doi-asserted-by":"crossref","first-page":"182e4","DOI":"10.1016\/j.ahj.2011.11.001","article-title":"Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction","volume":"163","author":"White","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2014.01.009_bib0215","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2014.01.009_bib0220","doi-asserted-by":"crossref","first-page":"768e2","DOI":"10.1016\/j.ahj.2012.02.018","article-title":"Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial","volume":"163","author":"Leonardi","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2014.01.009_bib0225","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","article-title":"Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial","volume":"373","author":"Montalescot","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2014.01.009_bib0230","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","article-title":"Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"31","author":"James","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2014.01.009_bib0235","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1056\/NEJMc1213509","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes","volume":"368","author":"Roe","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2014.01.009_bib0240","doi-asserted-by":"crossref","first-page":"d3527","DOI":"10.1136\/bmj.d3527","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"342","author":"James","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.acvd.2014.01.009_bib0245","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2014.01.009_bib0250","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1161\/CIRCULATIONAHA.109.900704","volume":"121","author":"Mahoney","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2014.01.009_bib0255","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jcin.2012.09.012","article-title":"Switching acute coronary syndrome patients from prasugrel to clopidogrel","volume":"6","author":"Kerneis","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.acvd.2014.01.009_bib0260","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2014.01.009_bib0265","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.2174\/138161212803251880","article-title":"Pharmacogenetics of clopidogre","volume":"18","author":"O\u2019Connor","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.acvd.2014.01.009_bib0270","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2014.01.009_bib0275","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2014.01.009_bib0280","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2014.01.009_bib0285","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213614000254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213614000254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:41:43Z","timestamp":1761745303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213614000254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1875213614000254"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2014.01.009","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New antiplatelet agents in the treatment of acute coronary syndromes","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2014.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}